AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00282464
Drug: Geodon (Ziprasidone)
RxNorm normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
Trial: NCT00612898
Drug: apricitabine
RxNorm normalized name: Apricitabine
DrugBank: Apricitabine (DB12855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg BID apricitabine orally for 48 weeks
Trial: NCT00612898
Drug: lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150mg BID lamivudine orally for 48 weeks
Trial: NCT03748043
Drug: Lactoferrin
RxNorm normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
Trial: NCT02202356
Drug: ALS-008176
RxNorm normalized name: ALS-008176
DrugBank: Lumicitabine (DB14808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01345058
Drug: lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day.
Trial: NCT01345058
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Low dose ≤1500 mg/day, High dose \>1500 mg/day
Trial: NCT02554279
Drug: menotropin
RxNorm normalized name: Menotropin
DrugBank: Menotropins (DB00032)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04288232
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal aflibercept Injection 2.0mg/0.05 ml
Trial: NCT02575066
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pazopanib QD 800 mg
Trial: NCT02239120
Drug: placebo to dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02239120
Drug: ASA 100 mg
RxNorm normalized name: ASA 100 MG Oral Tablet
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active comparator drug
Trial: NCT02239120
Drug: dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active drug
Trial: NCT03473418
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole as a topical vaginal gel
Trial: NCT03473418
Drug: Terconazole
RxNorm normalized name: Terconazole
DrugBank: Terconazole (DB00251)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terconazole 80 mg as a topical vaginal cream
Trial: NCT04037878
Drug: PCIA Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
Trial: NCT01470443
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130mg/㎡, day 1, every 3 weeks
Trial: NCT01470443
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
Trial: NCT02822547
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Peginterferon alfa-2a according to the standard medical practice
Trial: NCT02414568
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine 120 mg/m2 (IV) Day 1
Trial: NCT02414568
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg/m² PO
Trial: NCT02414568
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastine 6 mg/m² IV
Trial: NCT01612143
Drug: setrobuvir
RxNorm normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg capsule formulation, single oral dose
Trial: NCT01612143
Drug: setrobuvir
RxNorm normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tablet formulation, single oral dose
Trial: NCT04133922
Drug: GLP-1
RxNorm normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glucagon-like peptide 1
Trial: NCT04133922
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
Trial: NCT00500656
Drug: Icatibant
RxNorm normalized name: Icatibant
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
Trial: NCT00500656
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
Trial: NCT01305135
Drug: azacitidine and idarubicin
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
Trial: NCT03739684
Drug: 18F-DCFPyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
Trial: NCT04133922
Drug: Dextrose 20 % in Water
RxNorm normalized name: dextrose 20 % in water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We are using Dextrose to maintain Euglycemia during the insulin clamp
Trial: NCT01119937
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18µg capsules for inhalation, delivered via HandiHaler®
Trial: NCT00567996
Drug: Indacaterol 150 μg
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol 150 μg once daily (o.d) inhaled
Trial: NCT00567996
Drug: Salmeterol 50 μg
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
Trial: NCT00567996
Drug: Placebo to Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo to Indacaterol inhaled via SDDPI.
Trial: NCT00567996
Drug: Placebo to Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo to salmeterol delivered via a proprietary dry powder inhaler
Trial: NCT00981942
Drug: Imatinib mesylate (Glivec)
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg, one tablet daily for 12 or 24 weeks
Trial: NCT04106024
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
Trial: NCT05449015
Drug: 1% atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
Trial: NCT00294385
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00294385
Drug: Gemcitabine, Docetaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
Trial: NCT00294385
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
Trial: NCT03475810
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-2 mg midazolam will be administered before spinal punction performed.
Trial: NCT03446144
Drug: IONIS-FB-Lrx
RxNorm normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
Trial: NCT01673282
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
Trial: NCT03158792
Drug: Enoxaparin 20Mg/0.2mL Prefilled Syringe
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20mg subcutaneously once daily
Trial: NCT03158792
Drug: Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
RxNorm normalized name: ENOXAPARIN 60MG/0.6ML INJ SYRINGE 0.6ML
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
Trial: NCT03255330
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
Trial: NCT03255330
Drug: Metamizol
RxNorm normalized name: Metamizol
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment
Trial: NCT03255330
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standardized treatment
Trial: NCT04200040
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
Trial: NCT01986777
Drug: lisdexamfetamine
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04381988
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg daily
Trial: NCT01323920
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1.3 mg/m\^2 IV
Trial: NCT01323920
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.05 mg/kg PO bid
Trial: NCT00081510
Drug: Lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00081510
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00782587
Drug: Chemophase
DrugBank: Hyaluronidase (human recombinant) (DB06205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
Trial: NCT02025621
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03909971
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ALK inhibitor-treated ALK-positive NSCL treatment
Trial: NCT04559529
Drug: Levetiracetam (LEV) 500 mg
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The levetiracetam pill will look just like the placebo pill.
Trial: NCT03564509
Drug: FE 999302 (1 μg) and follitropin delta
RxNorm normalized name: .DELTA.-TOCOPHEROL
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
Trial: NCT03564509
Drug: FE 999302 (2 μg) and follitropin delta
RxNorm normalized name: .DELTA.-TOCOPHEROL
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Trial: NCT03564509
Drug: FE 999302 (4 μg) and follitropin delta
RxNorm normalized name: .DELTA.-TOCOPHEROL
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Trial: NCT03564509
Drug: FE 999302 (8 μg) and follitropin delta
RxNorm normalized name: .DELTA.-TOCOPHEROL
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Trial: NCT03564509
Drug: FE 999302 (12 μg) and follitropin delta
RxNorm normalized name: .DELTA.-TOCOPHEROL
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Trial: NCT04291001
Drug: oral ulipristal acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is an FDA-approved oral emergency contraceptive
Trial: NCT00689273
Drug: PF-04136309
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
Trial: NCT00216866
Drug: Dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00216866
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005646
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
Trial: NCT00098982
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00098982
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01126671
Drug: Supplemental Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.
Trial: NCT02361723
Drug: BGB-290
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00852371
Drug: sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/kg po once on day 0
Trial: NCT00852371
Drug: amodiaquine + sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
Trial: NCT00852371
Drug: dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
Trial: NCT00933413
Drug: LACTIC ACID(ND)
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment duration: 21 consecutive days
Trial: NCT00705744
Drug: Lactic acid (Dermacyd Femina)
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00459056
Drug: Carvedilol CR + Lisinopril
RxNorm normalized name: Carvedilol
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
Trial: NCT00459056
Drug: Lisinopril + HCTZ
RxNorm normalized name: hydrochlorothiazide / lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
Trial: NCT04134403
Drug: STASIS
RxNorm normalized name: Restasis
DrugBank: Ferric sulfate (DB11171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
Trial: NCT00573287
Drug: clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clozapine--tabs, 450mg. max, daily, 24 weeks
Trial: NCT00573287
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: risperidone--tabs, 6mg max, daily, 24 weeks
Trial: NCT01715129
Drug: Triptorelin Pamoate 11.25mg
RxNorm normalized name: TRIPTORELIN PAMOATE 11.25MG/VIL INJ
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03337672
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
Trial: NCT03337672
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
Trial: NCT00959972
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
Trial: NCT00959972
Drug: Transdermal Nicotine Patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
Trial: NCT03956368
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg (every evening orally) for 8 weeks.
Trial: NCT01478360
Drug: AIN457 (secukinumab)
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab intravenous injection
Trial: NCT02637284
Drug: Bepecin
RxNorm normalized name: Bepecin
DrugBank: BPC-157 (DB11882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics.
Trial: NCT01610687
Drug: GW-1000-02
RxNorm normalized name: GW-559090
DrugBank: GW-559090 (DB06508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
Trial: NCT00486876
Drug: Dextofisopam
RxNorm normalized name: Dextofisopam
DrugBank: Dextofisopam (DB06582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
Trial: NCT02248220
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no